Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

New data suggest that lenacapavir delivered just once per year could be as effective for HIV prevention as the twice-yearly ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

New real-world and implementation study data highlight the efficacy of ViiV’s long-acting injectables for HIV prevention and ...